Oncotarget is a multidisciplinary conventional journal which is accessed freely. The journal publishes weekly issues online whereby every paper or issue can be printed for other purposes. Our central goal is to make scientific outcomes quickly and generally accessible. That enables augmenting of the effect of research through insightful review permitting extraordinary discoveries to get shared easily. Another objective is to wipe out the gap between specialties while interfacing the diverse fields of biomedical science. More so, the journal encourages utilizations of essential and clinical science in fighting diseases.

Under the authority of the most conspicuous researchers, the journal helps all scientists add to the progressing of science. The ultimate goal of Oncotarget is to ensure people live without diseases, whilst, the achievement of Oncotarget has prompted to launching of different sections beyond oncology. Oncotarget is a week by week peer-assessed medical journal covering research on different parts of oncology. The journal was built up in 2010 and publishing is conducted by Impact Journals with Mikhail Blagosklonny & Andrei V as the chief editors.

The peer-reviewed journal that is published by Impact Journals, focuses on the potential therapy targets, pathological basis of different cancers and treatment protocols applied to boost the management of cancer victims. Likewise, the journal concentrates on the effect of new therapeutic agents, management programs and protocols on patients’ perspectives like adherence, satisfaction and quality of lives. Oncotarget explores the evidences behind the existing and new therapies in matters of improving results and more importantly, seeks in defining their usage in terms of optimum uptake and including acceptance by patient & healthcare professionals.

Oncotarget’s mission is to make results of scientific studies widely and rapidly accessible while optimizing the effect of research through perceptive review. The journal ensures exceptional discoveries are shared fast while eradicating the border between different fields. With Oncotarget, linking of various biomedical science fields has become easier while it has enabled fostering of basic & advanced knowledge in fighting diseases. Under the management of most recognized scientists, Oncotarget assists all researchers to contribute to the advance of science while ensuring fighting diseases in life is the key goal. The journal’s success has prompted the launching of different sections beyond oncology and Oncotarget is still making a major impact.

Follow Oncotarget journal on Twitter.

Seattle Genetics has increased its public stock offering to the public from $480 million to $552 million. The company has been able to raise its offering by exercising its over-allotment power.
Seattle Genetics’ CEO, Clay Siegall, said that the company decided to increase its allotment because many investors had interests in the company. Mr. Clay Siegall stated that the invested funds would not only be used to develop their drug pipeline but shall also be used to expand the company’s production of the cancer drug, Adcetrics.
The company shall also invest some of the funds to develop other infrastructures, expand its customer base, and increase its employees’ productivity through training. Mr. Clay also stated that the company is projected to be hiring up to 100 new employees annually.
He said that the firm’s workforce is expected to comprise of over 1300 people by 2020 if his projections are right. Responding to the company’s projected growth, its management seeks to lease bigger offices and may vacate their current location at Canyon Park building.
Clay Siegall founded Seattle Genetics over 18 years ago but the firm is yet to break even. Mr. Clay said that the firm’s inability to attain profitability was not an immediate concern to them because their current plan is to expand operations and not to achieve profitability.
The CEO also revealed that the company could be profitable if its leadership was to divert its focus from expansion. However, Mr. Clay maintained, the company’s leadership was focused on implementing growth and expansion plans that made it hard for the firm to break even.
Clay Siegall is the founder of Seattle Genetics and has been serving the company as its CEO since its inception. He holds a P.H.D in genetics from George Washington University. He also holds a bachelor’s degree in science (zoology) from Maryland University.

Before founding Seattle Genetics, Clay Siegall worked with Bristol-Myers Squibb Pharmaceutical Research Institute. He was named the entrepreneur of the year by Northwest Ernst and Young in 2012. He was also honored as the alumnus of the year for University of Maryland in 2013.